| | | | |
CUSIP No. 39536G 105 | | 13D | | Page 6 of 7 pages |
Explanatory Note
This Amendment No. 2 (this “Amendment No. 2”) to this Statement on Schedule 13D amends and supplements the Statement on Schedule 13D (the “Statement”) previously filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on February 11, 2022 and the Amendment No. 1 filed with the SEC on June 5, 2023, with respect to the Common Stock, par value $0.0001 per share (the “Common Stock”), of GreenLight Biosciences Holdings, PBC, a Delaware public benefit corporation (the “Issuer” or the “Company”). Capitalized terms used herein and not otherwise defined have the meanings assigned to such terms in the Statement. Except as otherwise provided herein, each Item of the Statement remains unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, where such information is relevant.
Item 4. | Purpose of Transaction. |
Item 4 of the Statement is hereby amended and supplemented as follows:
Consummation of Merger
On July 24, 2023, pursuant to that certain Agreement and Plan of Merger (the “Merger Agreement”), by and among the Issuer, SW ParentCo, Inc., a Delaware corporation (“Parent”), and SW MergerCo, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), Merger Sub merged with and into the Issuer (the “Merger”), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent.
Immediately prior to the effective time of the Merger, pursuant to the Merger Agreement and Contribution and Exchange Agreement, each of Kodiak III and Kodiak III-E contributed all of their respective shares of Common Stock to Parent in exchange for shares of Series A-2 Preferred Stock of Parent.
Item 5. | Interest in Securities of the Issuer. |
Item 5 of the Statement is hereby amended and restated in its entirety as follows:
| | |
(a)-(b) | | This Amendment No. 2 is being filed on behalf of the Reporting Persons to report that, as of July 24, 2023, the Reporting Persons do not beneficially own any shares of Common Stock. |
| |
(c) | | Except as described in Item 4, during the past 60 days, none of the Reporting Persons has effected any transactions with respect to the Common Stock. |
| |
(d) | | Not applicable. |
| |
(e) | | As of July 24, 2023, the Reporting Persons ceased to be the beneficial owners of more than five percent of the outstanding shares of Common Stock. |